COMPARISON OF EFFICACY AND SAFETY OF LULICONAZOLE 1% CREAM VERSUS AMOROLFINE 0.25% CREAM IN THE TREATMENT OF TINEA CRURIS
Main Article Content
Keywords
tinea cruris, luliconazole cream, amorolfine, randomised study and safety
Abstract
Background: Tinea cruris, commonly referred to as jock itch, is a prevalent superficial fungal infection caused by dermatophytes, leading to discomfort and recurrent episodes. The management of tinea cruris requires effective antifungal therapy to ensure complete eradication and prevent recurrence. This randomized, controlled study compares the efficacy and safety of Luliconazole 1% cream and Amorolfine 0.25% cream in 100 patients diagnosed with tinea cruris.
Materials and Methods: A randomized, controlled trial was conducted on 100 patients diagnosed with tinea cruris. Participants were divided into two groups: Group A (Luliconazole 1%) and Group B (Amorolfine 0.25%). Clinical improvement, mycological cure, and adverse effects were assessed over a four-week period.
Results: The results revealed that Luliconazole achieved an 85% clinical cure rate and a 90% mycological cure rate, whereas Amorolfine exhibited a 72% clinical cure rate and an 80% mycological cure rate. Recurrence rates were significantly lower in the Luliconazole group (5%) compared to the Amorolfine group (12%). Patients treated with Luliconazole reported faster symptom relief, with noticeable improvement within the first week of therapy. Additionally, Luliconazole was associated with fewer adverse effects, predominantly mild irritation in 3% of patients, whereas Amorolfine caused mild erythema and burning sensations in 7% of cases. Statistical analysis indicated a significant difference in treatment efficacy (p<0.05) favoring Luliconazole.
Conclusion: These findings suggest that Luliconazole 1% is a more effective and safer alternative for treating tinea cruris. Further large-scale studies are recommended to validate these results.
References
2. Jerajani HR, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol. 2013;58(1):34-38.
3. Martinez-Rossi NM, Bitencourt TA, Peres NTA, et al. Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus. Front Microbiol. 2018;9:1108.
4. Polak A. Preclinical data and mode of action of amorolfine. Dermatology. 1992;184(Suppl 1):3-7.
5. Singh BSTP, Tripathy T, Kar BR, Ray A. Clinicomycological Study of Dermatophytosis in a Tertiary Care Hospital in Eastern India: A Cross-sectional Study. Indian Dermatol Online J. 2019;11(1):46-50.
6. Watanabe S, Takahashi H, Nishikawa T, et al. A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses. 2006;49(3):236-241.
7. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;7(2):77-86.
8. Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid.2014;9:113-124.
9. Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol. 1992;17(Suppl 1):61-70.
10. Tanaka T, Satoh T, Yokozeki H. Allergic contact dermatitis from luliconazole: implication of the dithioacetal structure. Acta Derm Venereol. 2007;87(3):271-272.
11. Chandana T, Saritha Ch, Puligilla S. Comparison of safety and efficacy of luliconazole and other antifungal agents. Int J Pharma Sci Res. 2014;5:1-9.
12. Prabha ML, Meenakshi B, Devi PN, Ramya JE, Balan CR. A randomized comparative study to assess the efficacy of topical luliconazole versus topical clotrimazole in tinea corporis and tinea cruris. Natl J Physiol, Pharm, Pharmacol.2019;9:756-62.
13. Balamuruganvelu S, Reddy SV, Babu G. Age and Genderwise Seasonal Distribution of Dermatophytosis in a Tertiary Care Hospital, Puducherry, India. J Clin Diagn Res. 2019;13(2):WC06-WC10.
14. Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 2009;1(1):51-54.
15. Agarwal US, Saran J, Agarwal P. Clinico-mycological study of dermatophytes in a tertiary care center in Northwest India. Indian J Dermatol Venereol Leprol. 2014;80(2):194.
16. Agrawal V, Shenoy MM, Pinto M, Asfiya MIA, Hegde S. Comparative study of efficacy of topical amorolfine, luliconazole, sertaconazole, and terbinafine in tinea corporis and tinea cruris. IP Indian J Clin Exp Dermatol.2019;5(2):111-115.
17. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2-15.
18. Hassanandani T, Panda A, Kar BR. Allergic contact dermatitis to luliconazole: An uncommon side effect of a commonly used drug. Indian J Drugs Dermatol. 2020;6:47-8.
19. Martinez-Rossi NM, Bitencourt TA, Peres NTA, et al. Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus. Front Microbiol.2018;9:1108.
Crossref
20. Tanaka T, Satoh T, Yokozeki H. Allergic contact dermatitis from luliconazole: implication of the dithioacetal structure. Acta Derm Venereol. 2007;87(3):271-272.
Crossref
21. Shaw D, Singh S, Dogra S, et al. MIC and upper limit of wild-type distribution for 13 antifungal agents against Trichophyton mentagrophytes-Trichophyton interdigitale complex of Indian origin. Antimicrob Agents Chemother.2020;64(4):e01964-19.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Shraddha Jaywantrao Patil
Assistant Professor, Dept. of Dermatology, Dr. D. Y Patil Medical College, Nerul, Navi Mumbai